

SUPPLEMENTARY DATA

Supplementary Table 1. Treatment Compliance

Infusions of ATG*	Treatment Group		
	ATG & GCSF No. (%)	ATG Only No. (%)	Placebo No. (%)
0	1 (3.4)	0 (0.0)	0 (0.0)
1	0 (0.0)	0 (0.0)	0 (0.0)
2	28 (96.6)	29 (100.0)	31 (100.0)
Total	29 (100.0)	29 (100.0)	31 (100.0)
Injections of GCSF*	ATG & GCSF No. (%)	ATG Only No. (%)	Placebo No. (%)
0	1 (3.4)	0 (0.0)	0 (0.0)
1	0 (0.0)	0 (0.0)	0 (0.0)
2	1 (3.4)	0 (0.0)	0 (0.0)
3	1 (0.0)	1 (3.4)	0 (0.0)
4	0 (0.0)	0 (0.0)	1 (3.2)
5	2 (6.9)	0 (0.0)	2 (6.5)
6	24 (82.8)	28 (96.6)	28 (90.3)
Total	29 (100.0)	29 (100.0)	31 (100.0)

*Or saline

SUPPLEMENTARY DATA

Supplementary Table 2. Course of Therapy Summary Showing Median and Range from Targets and Total Number Treated

Course of Therapy & Statistic	ATG & GCSF Days (No.)	ATG Only Days (No.)	Placebo Days (No.)
ATG course 1			
Median	0	0	0
Range	-1 to +1	-1 to 0	-1 to +1
No.	(28)	(29)	(31)
ATG course 2			
Median	0	0	0
Range	-1 to 0	-1 to 0	-1 to 0
No.	(28)	(29)	(31)
GCSF Injection 1			
Median	0	0	0
Range	-1 to 0	-1 to 0	-1 to 0
No.	(28)	(29)	(31)
GCSF Injection 2			
Median	1	1	1
Range	-2 to +5	-3 to +5	-3 to +6
No.	(28)	(29)	(31)
GCSF Injection 3			
Median	1	1	1
Range	-3 to 15	-2 to +5	-3 to +16
No.	(27)	(29)	(31)
GCSF Injection 4			
Median	1	0	0
Range	-3 to +15	-2 to +2	-3 to +17
No.	(26)	(28)	(31)
GCSF Injection 5			
Median	2	0	1
Range	-4 to 17	-3 to +5	-3 to +17
No.	(26)	(28)	(30)
GCSF Injection 6			
Median	1	1	0.5
Range	-3 to +3	-3 to +5	-3 to +4
No.	(24)	(28)	(28)

SUPPLEMENTARY DATA


Supplementary Table 3. 12 Month Predicted Means for Complete Blood Count and Differential by Treatment Group

Blood Constituents	Placebo	ATG Only	ATG and GCSF
WBC	5.49 (5.06, 5.95)	5.05 (4.67, 5.47)	5.39 (4.94, 5.87)
RBC	4.75 (4.66, 4.84)	4.77 (4.69, 4.86)	4.7 (4.61, 4.79)
Hemoglobin	13.7 (13.5, 14)	13.6 (13.3, 13.8)	13.7 (13.4, 14)
Hematocrit	40.8 (40.1, 41.6)	40.5 (39.8, 41.3)	40.6 (39.9, 41.4)
Platelets	229 (217, 240)	236 (225, 249)	225 (214, 237)
Neutrophils	2.80 (2.46, 3.2)	2.71 (2.38, 3.1)	3.05 (2.66, 3.52)
Lymphocytes*	2.03 (1.83, 2.27)	1.45 (1.3, 1.62)	1.61 (1.44, 1.8)
Monocytes	0.483 (0.43, 0.539)	0.43 (0.378, 0.484)	0.434 (0.381, 0.489)
Eosinophils	0.162 (0.137, 0.191)	0.161 (0.136, 0.192)	0.180 (0.151, 0.216)
Basophils	0.0187 (0.0105, 0.0293)	0.0177 (0.00964, 0.0282)	0.0184 (0.01, 0.0293)


* Both experimental treatment groups are statistically significantly different from the placebo group. Predicted Means (ANCOVA adjusting for age, baseline level, and sex) and 95% Confidence Intervals of several blood constituents from the CBC by treatment group

SUPPLEMENTARY DATA


Supplementary Figure 1a-c. Individual Treatment times in the ATG/GCSF, ATG alone, and Placebo groups, respectively. ATG/Placebo Doses are show in filled triangles and GCSF/Placebo doses are shown in open circles.



Individual Treatment Times for ATG Only Group




Individual Treatment Times for Placebo Group



SUPPLEMENTARY DATA


Supplementary Figure 2a-c. Spaghetti Plots of Individual C-Peptide AUC Over Time in the ATG/GCSF, ATG alone, and Placebo Groups, respectively. AUC C-peptide for each subject is shown over time as open circles with connecting lines between study time points.

Individual C-Peptide AUC Means Over Time for
ATG & GCSF Group




SUPPLEMENTARY DATA

Individual C-Peptide AUC Means Over Time for
ATG Only Group




SUPPLEMENTARY DATA

Individual C-Peptide AUC Means Over Time for Placebo Group




SUPPLEMENTARY DATA

Supplementary Figure 3. Decline in C-Peptide AUC Mean Over Time by Treatment Group. Mean AUC C-peptide adjusted for age, sex, and baseline value and shown over time in the ATG/GCSF, ATG alone, and Placebo groups. AUC C-peptide was significantly higher in ATG alone vs Placebo ($p=0.0003$) and was not significantly higher in ATG/GCSF vs placebo ($p=0.031$), using a one-sided $p < 0.025$ for significance.




SUPPLEMENTARY DATA

Supplementary Figure 4. Mixed Meal Stimulated Glucose AUC Mean. In a secondary analysis, AUC Glucose following the MMTT was calculated and adjusted for baseline glucose, age, and gender using an ANCOVA model. The AUC glucose was significantly lower in the ATG group ($p=0.005$) when compared to the placebo group at the 6, 9, and 12 month assessments.




SUPPLEMENTARY DATA

Supplementary Figure 5. CD4 and CD8 Counts over Time. Following treatment with low-dose ATG or low-dose ATG/GCSF CD4 counts were reduced while CD8 counts were unaffected. This resulted in a reduced CD4/CD8 ratio in subjects who received low dose ATG or low-dose ATG/GCSF.



SUPPLEMENTARY DATA

CD8 Over Time By Treatment Group



SUPPLEMENTARY DATA

ONLINE APPENDIX. Type 1 Diabetes TrialNet ATG-GCSF Study Group

Steering Committee: C. Greenbaum (Benaroya Research Institute, Chair), M. Atkinson (University of Florida), D. Baidal (University of Miami), M. Battaglia (San Raffaele University), D. Becker (University of Pittsburgh), P. Bingley (University of Bristol), E. Bosi (San Raffaele University), J. Buckner (Benaroya Research Institute), M. Clements (The Children's Mercy Hospital), P. Colman (Walter & Eliza Hall Institute of Medical Research), L. DiMeglio (Indiana University), C. Evans-Molina (Indiana University), S. Gitelman, (University of California, San Francisco), R. Goland (Columbia University), P. Gottlieb (Barbara Davis Center for Childhood Diabetes), K. Herold (Yale University), M. Knip (University of Helsinki), J. Krischer (University of South Florida), A. Lernmark (Skane University), W. Moore (The Children's Mercy Hospital), A. Moran (University of Minnesota), A. Muir (Emory University), J. Palmer (University of Washington), M. Peakman (King's College), L. Philipson (University of Chicago), P. Raskin (University of Texas Southwestern), M. Redondo (Baylor University), H. Rodriguez (University of South Florida), W. Russell (Vanderbilt University), L. Spain (National Institute of Diabetes and Digestive and Kidney Diseases [NIDDK]), D.A. Schatz (University of Florida), J. Sosenko (University of Miami), D. Wherrett (University of Toronto), D. Wilson (Stanford University), W. Winter (University of Florida), A. Ziegler (Forschergruppe Diabetes); Previous Members: M. Anderson (University of California, San Francisco), P. Antinozzi (Wake Forest University), C. Benoist (Joslin Diabetes Center), J. Blum (Indiana University), K. Bourcier, P. Chase (Barbara Davis Center for Childhood Diabetes), M. Clare-Salzler (University of Florida), R. Clynes (Columbia University), C. Cowie (NIDDK), G. Eisenbarth (Barbara Davis Center for Childhood Diabetes), C. G. Fathman (Stanford University), G. Grave (National Institute of Child Health and Human Development), L. Harrison (Walter & Eliza Hall Institute of Medical Research), B. Hering (University of Minnesota), R. Insel (Juvenile Diabetes Research Foundation), S. Jordan (Cedars Sinai Medical Center), F. Kaufman (Children's Hospital Los Angeles), T. Kay (St Vincent's Institute of Medical Research), N. Kenyon (University of Miami), R. Klines (Columbia University), J. Lachin (George Washington University), E. Leschek (NIDDK), J. Mahon (University of Western Ontario), J.B. Marks (University of Miami), R. Monzavi (Children's Hospital Los Angeles), K. Nanto-Salonen (University of Turku), G. Nepom (Benaroya Research Institute), T. Orban (Joslin Diabetes Center), R. Parkman (Children's Hospital Los Angeles), M. Pescovitz (Indiana University), J. Peyman (National Institute of Allergy and Infectious Disease) A. Pugliese (University of Miami), J. Ridge (NIDDK), B. Roep (Leiden University Medical Center), M. Roncarolo (San Raffaele University), P. Savage (NIDDK), O. Simell (University of Turku), R. Sherwin (Yale University), M. Siegelman (University of Texas Southwestern), J.S. Skyler (University of Miami), A. Steck (Barbara Davis Center for Childhood Diabetes), J. Thomas (Vanderbilt University), M. Trucco (University of Pittsburgh), J. Wagner (University of Minnesota).

Executive Committee: Katarzyna Bourcier, Carla J. Greenbaum, Jeffrey P. Krischer, Ellen Leschek, Lisa Raffkin, Lisa Spain. Past Members: Catherine Cowie, Mary Foulkes, Richard Insel, Heidi Krause-Steinrauf, John M. Lachin, Saul Malozowski, John Peyman, John Ridge, Peter Savage, Jay S. Skyler, Stephanie J. Zafonte.

SUPPLEMENTARY DATA

For the ATG-GCSF Study, the following individuals were involved:

Chairman's Office: Carla J. Greenbaum, Lisa Rafkin, Jay M. Sosenko. Past Members: Jay S. Skyler, Norma S. Kenyon, Irene Santiago.

TrialNet Coordinating Center (University of South Florida): Jeffrey P. Krischer, Brian Bundy, Michael Abbondandolo, Timothy Adams, Darlene Amado, Ilma Asif, Matthew Boonstra, David Boulware, Brian Bundy, Cristina Burroughs, David Cuthbertson, Christopher Eberhard, Steve Fiske, Julie Ford, Jennifer Garmeson, Heather Guillette, Susan Geyer, Brian Hays, Courtney Henderson, Martha Henry, Kathleen Heyman, Belinda Hsiao, Christina Karges, Amanda Kinderman, Lindsay Lane, Ashley Leinbach, Shu Liu, Jennifer Lloyd, Jamie Malloy, Kristin Maddox, Julie Martin, Jessica Miller, Margaret Moore, Sarah Muller, Thuy Nguyen, Ryan O'Donnell, Melissa Parker, MJ Pereyra, Nichole Reed, Amy Roberts, Kelly Sadler, Tina Stavros, Roy Tamura, Keith Wood, Ping Xu, Kenneth Young. Past Staff Members: Persida Alies, Franz Badias, Aaron Baker, Monica Bassi, Craig Beam, David Boulware, London Bounmananh, Susan Bream, Mary Deemer, Doug Freeman, Jessica Gough, Jinin Ginem, Moriah Granger, Mary Holloway, Michelle Kieffer, Page Lane, Pat Law, Cristin Linton, Lavanya Nallamshetty, Vanessa Oduah, Yazandra Parrimon, Kate Paulus, Jennifer Pilger, Joy Ramiro, AQesha Luvon Ritzie, Archana Sharma, Audrey Shor, Xiaohong Song, Amanda Terry, Jeanne Weinberger, Margaret Wootten.

NIDDK Staff: Judith Fradkin, Ellen Leschek, Lisa Spain. Past Members: Catherine Cowie, Saul Malozowski, Peter Savage.

Data Safety and Monitoring Board: Gerald Beck (Cleveland Clinic), Emily Blumberg (University of Pennsylvania), Chair, Rose Gubitosi-Klug (Case Western Reserve), Lori Laffel (Joslin Diabetes Center), Robert Veatch (Georgetown University), Dennis Wallace (Research Triangle Institute). Past Members: Jonathan Braun (University of California Los Angeles), David Brillon (Cornell University), Ake Lernmark (Lund University), Bernard Lo (University of California San Francisco), Herman Mitchell (Rho Inc.), Ali Naji (University of Pennsylvania), Jorn Nerup (University of Copenhagen), Trevor Orchard (University of Pittsburgh), Michael Steffes (University of Minnesota), Anastasios Tsiatis (North Carolina State University), Bernard Zinman (University of Toronto).

Infectious Disease Safety Committee: Brett Loechelt (Children's National Medical Center) (Medical Monitor), Lindsey Baden (Harvard University), Michael Green (University of Pittsburgh), Adriana Weinberg (University of Colorado).

Laboratory Directors: Santica Marcovina, Jerry P. Palmer (University of Washington), Adriana Weinberg, Liping Yu (University of Colorado, Barbara Davis Center for Childhood Diabetes), William Winter (University of Florida) (Past Member: George S. Eisenbarth (late)).

TrialNet Clinical Network Hub: Annie Shultz, Emily Batts, Kristin Fitzpatrick, Mary Ramey, Randy Guerra, Christopher Webb. Past Member: Melita Romasco.

SUPPLEMENTARY DATA

Clinical Center Staff Involved in this Protocol:

Benaroya Research Institute, Seattle, Washington: Carla Greenbaum, Sandra Lord, Dana VanBuecken, Wei Hao, Marli McCulloch, Deborah Hefty, Kim Varner

Columbia University, New York, New York: Robin Goland, Ellen Greenberg, Sarah Pollack

Greenville Health System Pediatric Endocrinology, Greenville, South Carolina: Bryce Nelson, Lisa Looper

Indiana University, Indianapolis, Indiana: Linda DiMeglio, Maria Spall, Carmella Evans-Molina, Manasa Mantravadi, Juan Sanchez, Maureen Mullen, Vanessa Patrick, Stephanie Woerner

Stanford University, Palo Alto, California: Darrell M. Wilson, Tandy Aye, Trudy Esrey, Karen Barahona, Bonita Baker, Hiyam Bitar, Catherine Ghodrat, Martha Hamilton

University of California, San Francisco, California: Stephen E. Gitelman, Christine T. Ferrara, Srinath Sanda, Rebecca Wesch, Christine Torok

University of Colorado Barbara Davis Center for Childhood Diabetes, Aurora, Colorado: Peter Gottlieb, Jordan Lykens, Carrie Brill, Aaron Michels, Allison Schauwecker

University of Florida, Gainesville, Florida: Michael J. Haller, Desmond A. Schatz, Mark A. Atkinson, Laura M. Jacobsen, Miriam Cintron, Todd M. Brusko, Clive H. Wasserfall, Clay E. Mathews

University of Miami Diabetes Research Institute, Miami, Florida: Jay S. Skyler, Jennifer M. Marks, David Baidal, Carlos Blaschke, Della Matheson

University of Minnesota, Minneapolis, Minnesota: Antoinette Moran, Brandon Nathan, Anne Street, Janice Leschyshyn, Beth Pappenfus, Brittney Nelson, Nancy Flaherty

University of Pittsburgh, Pittsburgh, Pennsylvania: Dorothy Becker, Kelly Delallo, David Groscost, Karen Riley

University of South Florida Diabetes Center, Tampa, Florida: Henry Rodriguez, Danielle Henson, Emily Eyth

Vanderbilt University, Nashville, Tennessee: William Russell, Anne Brown, Faith Brendall

Yale University, New Haven, Connecticut: Kevan Herold, Laurie Feldman